The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Abstract
Owing to the dysregulation of protein kinase activity in many diseases including cancer, the protein kinase enzyme family has become one of the most important drug targets in the 21st century. There are 62 FDA-approved therapeutic agents that target about two dozen different protein kinases and eight of these were approved in 2020. All of the FDA-approved drugs are orally effective with the exception of netarsudil (a ROCK1/2 non-receptor protein-serine/threonine kinase antagonist given as an eye drop for the treatment of glaucoma) and temsirolimus (an indirect mTOR inhibitor given intravenously for the treatment of renal cell carcinoma). Of the approved drugs, ten target protein-serine/threonine protein kinases, four are directed against dual specificity protein kinases (MEK1/2), thirteen block non-receptor protein-tyrosine kinases, and 35 target receptor protein-tyrosine kinases. The data indicate that 55 of these drugs are prescribed for the treatment of neoplasms (52 against solid tumors including breast, lung, and colon, nine against non-solid tumors such as leukemias, and four against both solid and non-solid tumors: acalabrutinib, ibrutinib, imatinib, and midostaurin). A total of three drugs (baricitinib, tofacitinib, upadacitinib) is used for the treatment of inflammatory diseases including rheumatoid arthritis. Seven of the approved drugs form covalent bonds with their target enzymes and are classified as TCIs (targeted covalent inhibitors). Of the 62 approved drugs, eighteen are used in the treatment of multiple diseases. Imatinib, for example, is approved for the treatment of eight different disorders. The most common drug targets of the approved pharmaceuticals include BCR-Abl, B-Raf, vascular endothelial growth factor receptors (VEGFR), epidermal growth factor receptors (EGFR), and ALK. The following eight drugs received FDA approval in 2020 for the treatment of the specified diseases: avapritinib and ripretinib (gastrointestinal stromal tumors), capmatinib (non-small cell lung cancer), pemigatinib (cholangiocarcinoma), pralsetinib and selpercatinib (non-small cell lung cancer, medullary thyroid cancer, differentiated thyroid cancer), selumetinib (neurofibromatosis type I), and tucatinib (HER2-positive breast cancer). All of the eight drugs approved in 2020 fulfill Lipinski's rule of five criteria for an orally effective medicine (MW of 500 Da or less, five or fewer hydrogen bond donors, 10 or fewer hydrogen bond acceptors, calculated log10 of the partition coefficient of five or less) with the exception of three drugs with a molecular weight greater that 500 Da: pralsetinib (534), selpercatinib (526) and ripretinib (510). This review summarizes the physicochemical properties of all 62 FDA-approved small molecule protein kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Colorectal cancer statistics, 2020
Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., Cercek, A., Smith, R. A., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21601 · Cited by 4,880
Scott, D. L., Wolfe, F., & Huizinga, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60826-4 · Cited by 3,013
Hanks, S. K., & Hunter, T. R. (1995) · PubMed · Cited by 2,518
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1
Hanks, S. K., & Hunter, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.8.7768349 · Cited by 2,318
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Knighton, D. R., Zheng, J., Ten Eyck, L. F., Ashford, V. A., Xuong, N.-H., Taylor, S. S., & Sowadski, J. M. (1991) · Science · doi:10.1126/science.1862342 · Cited by 1,759
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
Self-citationThe JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Self-citationTucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914609 · Cited by 1,326
MET signalling: principles and functions in development, organ regeneration and cancer
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3012 · Cited by 1,240
The role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
Molecular cloning of a new transforming gene from a chemically transformed human cell line
Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., & Vande Woude, G. F. (1984) · Nature · doi:10.1038/311029a0 · Cited by 989
Protein kinases: evolution of dynamic regulatory proteins
Taylor, S. S., & Kornev, A. P. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.09.006 · Cited by 945
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
Gastrointestinal stromal tumours: origin and molecular oncology
Corless, C. L., Barnett, C. M., & Heinrich, M. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3143 · Cited by 891
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Self-citationHeinrich, M. C., Maki, R. G., Corless, C. L., Antonescu, C. R., Harlow, A., Griffith, D., Town, A., Mckinley, A., Ou, W.-B., Fletcher, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7461 · Cited by 797
Kornev, A. P., Haste, N. M., Taylor, S. S., & Ten Eyck, L. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607656103 · Cited by 762
Tofacitinib versus methotrexate in rheumatoid arthritis
Lee, E. B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J. D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Zang, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310476 · Cited by 711
Property distribution of drug-related chemical databases*
Oprea, T. I. (2000) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008130001697 · Cited by 628
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.01.003 · Cited by 607
Self-citationProperties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Roskoski, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 559
Self-citationProperties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Self-citationA historical overview of protein kinases and their targeted small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.010 · Cited by 526
Self-citationNovel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Eder, J. P., Vande Woude, G. F., Boerner, S. A., & LoRusso, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1306 · Cited by 522
Treatment of Older Patients with Mantle-Cell Lymphoma
Kluin-Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J., Trneny, M., Geisler, C. H., Stilgenbauer, S., Thieblemont, C., Vehling-Kaiser, U., Doorduijn, J. K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200920 · Cited by 520
Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
Zuccotto, F., Ardini, E., Casale, E., & Angiolini, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901443h · Cited by 518
Liao, J. J.-L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0608107 · Cited by 507
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.014 · Cited by 487
Self-citationTyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
A helix scaffold for the assembly of active protein kinases
Kornev, A. P., Taylor, S. S., & Ten Eyck, L. F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807988105 · Cited by 442
Kinase inhibition in autoimmunity and inflammation
Zarrin, A. A., Bao, K., Lupardus, P., & Vucic, D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0082-8 · Cited by 431
The first general index of molecular complexity
Bertz, S. H. (1981) · Journal of the American Chemical Society · doi:10.1021/ja00402a071 · Cited by 414
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.035 · Cited by 393
Self-citationIn vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Parmentier, J. M., Voss, J., Graff, C., Schwartz, A., Argiriadi, M., Friedman, M., Camp, H. S., Padley, R. J., George, J. S., Hyland, D., et al. (2018) · BMC Rheumatology · doi:10.1186/s41927-018-0031-x · Cited by 390
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Dar, A. C., & Shokat, K. M. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090308-173656 · Cited by 388
Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378
RAF protein-serine/threonine kinases: Structure and regulation
Roskoski, R. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.07.092 · Cited by 376
Self-citationJanus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.038 · Cited by 373
Self-citationGuo, Y., Liu, Y., Hu, N., Yu, D., Zhou, C., Shi, G., Zhang, B., Wei, M., Liu, J., Luo, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00687 · Cited by 359
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
Di Renzo, M. F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., De Stefani, A., Valente, G., Giordano, S., Cortesina, G., & Comoglio, P. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203455 · Cited by 332
Steroid-hormone receptors in breast cancer
Wittliff, J. L. (1984) · Cancer · doi:10.1002/1097-0142(19840201)53:3+<630::aid-cncr2820531308>3.0.co;2-3 · Cited by 325
Erratum: Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.52 · Cited by 311
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 308
Self-citationAnaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, R. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 303
Self-citationKawamura, M., McVicar, D. W., Johnston, J. A., Blake, T. B., Chen, Y. Q., Lal, B. K., Lloyd, A. R., Kelvin, D. J., Staples, J. E., Ortaldo, J. R., et al. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6374 · Cited by 302
KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space
van Linden, O. P. J., Kooistra, A. J., Leurs, R., de Esch, I. J. P., & de Graaf, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400378w · Cited by 298
Dynamics-Driven Allostery in Protein Kinases
Kornev, A. P., & Taylor, S. S. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.09.002 · Cited by 284
Silverman, I. M., Hollebecque, A., Friboulet, L., Owens, S., Newton, R. C., Zhen, H., Féliz, L., Zecchetto, C., Melisi, D., & Burn, T. C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0766 · Cited by 283
McInnes, I. B., Byers, N. L., Higgs, R. E., Lee, J., Macias, W. L., Na, S., Ortmann, R. A., Rocha, G., Rooney, T. P., Wehrman, T., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1964-1 · Cited by 281
MET: a promising anticancer therapeutic target
Peters, S., & Adjei, A. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.71 · Cited by 280
Smith, B. D., Kaufman, M. D., Lu, W.-P., Gupta, A., Leary, C. B., Wise, S. C., Rutkoski, T. J., Ahn, Y. M., Al-Ani, G., Bulfer, S. L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.04.006 · Cited by 279
Madhusudan, Trafny, E. A., Xuong, N., Adams, J. A., Eyck, L. F. T., Taylor, S. S., & Sowadski, J. M. (1994) · Protein Science · doi:10.1002/pro.5560030203 · Cited by 274
Defining the conserved internal architecture of a protein kinase
Kornev, A. P., & Taylor, S. S. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.10.017 · Cited by 266
Liu, X., Wang, Q., Yang, G., Marando, C., Koblish, H. K., Hall, L. M., Fridman, J. S., Behshad, E., Wynn, R., Li, Y., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1157 · Cited by 265
Subbiah, V., Shen, T., Terzyan, S. S., Liu, X., Hu, X., Patel, K. P., Hu, M. I.-N., Cabanillas, M. E., Behrang, A., Meric‐Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.599 · Cited by 265
Roskoski, R. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.010 · Cited by 260
Self-citationCyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.012 · Cited by 237
Self-citationKulukian, A., Lee, P., Taylor, J., Rosler, R., de Vries, P., Watson, D., Forero-Torres, A., & Peterson, S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0873 · Cited by 222
Hoy, S. M. (2020) · Drugs · doi:10.1007/s40265-020-01330-y · Cited by 221
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.001 · Cited by 218
Self-citationDeciphering the Structural Basis of Eukaryotic Protein Kinase Regulation
Meharena, H. S., Chang, P., Keshwani, M. M., Oruganty, K., Nene, A. K., Kannan, N., Taylor, S. S., & Kornev, A. P. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001680 · Cited by 208
AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective: Miniperspective
Myers, S. H., Brunton, V. G., & Unciti-Broceta, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01273 · Cited by 203
Protein kinase biochemistry and drug discovery
Schwartz, P. A., & Murray, B. W. (2011) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2011.07.004 · Cited by 201
The changing landscape of biosimilars in rheumatology
Dörner, T., Strand, V., Cornes, P., Gonçalves, J., Gulácsi, L., Kay, J., Kvien, T. K., Smolen, J., Tanaka, Y., & Burmester, G. R. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209166 · Cited by 194
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 194
Self-citationApproaches to discover non-ATP site kinase inhibitors
Gavrin, L. K., & Saiah, E. (2013) · MedChemComm · doi:10.1039/c2md20180a · Cited by 184
New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
Lamba, V., & Ghosh, I. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800672813 · Cited by 182
Involvement of platelet‐derived growth factor ligands and receptors in tumorigenesis
Heldin, C. ‐., Lennartsson, J., & Westermark, B. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12690 · Cited by 181
Molecular inflation, attrition and the rule of five
Leeson, P. D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.018 · Cited by 179
Neurofibromin Structure, Functions and Regulation
Bergoug, M., Doudeau, M., Godin, F., Mosrin, C., Vallée, B., & Bénédetti, H. (2020) · Cells · doi:10.3390/cells9112365 · Cited by 178
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.021 · Cited by 170
Self-citationKLIFS: an overhaul after the first 5 years of supporting kinase research
Kanev, G. K., de Graaf, C., Westerman, B. A., de Esch, I. J. P., & Kooistra, A. J. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa895 · Cited by 163
A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src
Liu, Y., Shah, K., Yang, F., Witucki, L. A., & Shokat, K. M. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00099-6 · Cited by 156
The Landscape of Atypical and Eukaryotic Protein Kinases
Kanev, G. K., de Graaf, C., de Esch, I. J. P., Leurs, R., Würdinger, T., Westerman, B. A., & Kooistra, A. J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.002 · Cited by 153
Roskoski, R. J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104567 · Cited by 153
Self-citationSyed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-019-01252-4 · Cited by 150
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.022 · Cited by 138
Self-citationDuggan, S. T., & Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01211-z · Cited by 134
Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.007 · Cited by 133
Self-citationMolecular complexity: a simplified formula adapted to individual atoms
Hendrickson, J. B., Huang, P., & Toczko, A. G. (1987) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00054a004 · Cited by 132
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.009 · Cited by 119
Self-citationRole of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
Roskoski, R. J., & Sadeghi‐Nejad, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.021 · Cited by 118
Self-citationGuidelines for preparing color figures for everyone including the colorblind
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.005 · Cited by 112
Self-citationThe new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
Bechman, K., Yates, M., & Galloway, J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104392 · Cited by 112
The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification
Wells, C. I., Al‐Ali, H., Andrews, D. M., Asquith, C. R. M., Axtman, A. D., Chung, M., Đikić, I., Ebner, D. V., Elkins, J. M., Ettmayer, P., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020566 · Cited by 109
Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01347-3 · Cited by 106
Redefining the Protein Kinase Conformational Space with Machine Learning
Ung, P. M. U., Rahman, R., & Schlessinger, A. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.05.002 · Cited by 104
Markham, A. (2020) · Drugs · doi:10.1007/s40265-020-01427-4 · Cited by 104
The JAK kinases: Not just another kinase drug discovery target
Wilks, A. F. (2008) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2008.07.020 · Cited by 97
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.011 · Cited by 94
Self-citationOrally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105422 · Cited by 93
Self-citationParticipation of ADP Dissociation in the Rate-Determining Step in cAMP-Dependent Protein Kinase
Zhou, J., & Adams, J. A. (1997) · Biochemistry · doi:10.1021/bi971438n · Cited by 91
Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
Bajusz, D., Ferenczy, G. G., & Keserű, G. M. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666170224121313 · Cited by 88
Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview
Fischer, P. M. (2016) · Medicinal Research Reviews · doi:10.1002/med.21409 · Cited by 84
Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB
Bournez, C., Carles, F., Peyrat, G., Aci‐Sèche, S., Bourg, S., Meyer, C., & Bonnet, P. (2020) · Molecules · doi:10.3390/molecules25143226 · Cited by 82
Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.020 · Cited by 80
Self-citationLee, A. (2020) · Drugs · doi:10.1007/s40265-020-01340-w · Cited by 80
KinaseMD: kinase mutations and drug response database
Hu, R., Xu, H., Jia, P., & Zhao, Z. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa945 · Cited by 78
Recent advances in the treatment of gastrointestinal stromal tumors
Serrano, C., & George, S. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014522491 · Cited by 68
Reichardt, P., Demetri, G. D., Gelderblom, H. A. J., Rutkowski, P. L., Im, S., Gupta, S., Kang, Y., Schöffski, P., Schuette, J., Soulières, D., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2051-5 · Cited by 67
Nemunaitis, J. J., Bauer, S., Blay, J., Choucair, K., Gelderblom, H. A. J., George, S., Schöffski, P., von Mehren, M., Zalcberg, J. R., Achour, H., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0633 · Cited by 56
Current status of MEK inhibitors in the treatment of plexiform neurofibromas
Gross, A. M., Dombi, E., & Widemann, B. C. (2020) · Child's Nervous System · doi:10.1007/s00381-020-04731-2 · Cited by 47
Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma
Gao, J., Inagaki, Y., Song, P., Qu, X., Kokudo, N., & Tang, W. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.11.011 · Cited by 46
Robarge, K. D., Lee, W., Eigenbrot, C. W., Ultsch, M. H., Wiesmann, C., Heald, R. A., Price, S., Hewitt, J. F. M., Jackson, P. S., Savy, P., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.08.008 · Cited by 44
Smith, G. F. (2009) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(09)04801-2 · Cited by 42
Roskoski, R. J. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.813015 · Cited by 39
Self-citationBahlawane, C., Eulenfeld, R., Wiesinger, M., Wang, J., Muller, A., Girod, A., Nazarov, P. V., Felsch, K., Vallar, L., Sauter, T., et al. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0096-8 · Cited by 35
Frame, M. C., & Roskoski, R. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.07199-5 · Cited by 32
Self-citationReddy, V., & Cohen, S. B. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00931-6 · Cited by 31
Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections
Bechman, K., Galloway, J. B., & Winthrop, K. L. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00350-w · Cited by 29
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box
Tarantino, P., Prat, A., Cortés, J., Cardoso, F., & Curigliano, G. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188487 · Cited by 27
Posttranslational modifications as therapeutic targets for intestinal disorders
Choo, J., Heo, G., Pothoulakis, C., & Im, E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105412 · Cited by 22
Surprising Non-Additivity of Methyl Groups in Drug–Kinase Interaction
Wienen-Schmidt, B., Schmidt, D., Gerber, H., Heine, A., Gohlke, H., & Klebe, G. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00476 · Cited by 20
Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods
Ekins, S., Litterman, N. K., Lipinski, C. A., & Bunin, B. A. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1779-y · Cited by 19
Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
Rizzo, A., Tavolari, S., Ricci, A. D., Frega, G., Palloni, A., Relli, V., Salati, M., Fenocchio, E., Massa, A., Aglietta, M., et al. (2020) · Cancers · doi:10.3390/cancers12113256 · Cited by 11
Available Therapies for Patients with Neurofibromatosis-Related Nervous System Tumors
Strowd, R. E., III (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00779-z · Cited by 8
Cited by
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
Roskoski, R. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107059 · Cited by 383
Self-citationThe role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175586 · Cited by 362
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Roskoski, R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106552 · Cited by 273
Self-citationSmall Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Metadata
- Authors
- Roskoski, R.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 165
- Pages
- 105463
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W3123446037
- Cited by
- 335
- References
- 130
- FWCI
- 20.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.